查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529888

急性骨髓性白血病治疗市场规模、份额和趋势分析报告：按疾病、治疗方法、给药途径、最终用途、地区和细分市场进行预测，2024-2030年

Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report By Disease (Myeloblastic Leukemia, Myelomonocytic Leukemia), By Treatment (Chemotherapy), By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 175 Pages | 商品交期: 2-10个工作天内

价格

市场规模及趋势

预计2023年全球急性骨髓性白血病治疗市场规模为31.8亿美元，预计2024年至2030年复合年增长率为10.44%。对先进疗法的需求不断增长也是推动该市场的一个主要因素。急性骨髓性白血病药物发生率增加是由于基因突变、不健康的生活方式、持续接触苯等有害化学物质以及辐射等因素造成的。此外，老年人口的增加和未满足的医疗保健需求的增加预计将进一步推动市场成长。美国癌症协会估计，到 2024 年，大约有 20,800 人将被诊断出患有急性骨髓性白血病。

急性骨髓性白血病（AML）治疗市场由与治疗药物和治疗相关的几个关键因素所驱动。关键驱动因素之一是新治疗方法的持续进步和核准。例如，2023年7月，FDA核准quizartinib（Vanflyta）合併标准化疗用于治疗新诊断的FLT3-ITD阳性AML成年患者。这项核准凸显了针对 AML 特定基因突变、改善患者预后和扩大治疗选择的标靶治疗的重要性。这些进步不仅提高了治疗方法的有效性，也为传统治疗方法选择有限的患者带来了新的希望。

另一个主要推动因素是製药公司对研发的大量投资。例如，2023 年 12 月授予的 600 万美元津贴用于开发高风险 AML 患者的新治疗方法，体现了 Masu 对这一领域创新的坚定承诺。这些投资对于发现新治疗方法和改进现有治疗方法至关重要，从而推动市场成长。此外，製药公司、研究机构和学术中心之间的合作和伙伴关係对于加速新的 AML治疗方法的开拓发展、进一步推动市场扩张至关重要。

儘管取得了这些进展，但 AML 治疗市场仍面临一些限制因素。主要挑战之一是新治疗方法的高成本。创新治疗方法的开发、核准和商业化通常非常昂贵，导致患者和医疗保健系统的成本高昂。这种财务负担可能会限制获得尖端治疗的机会，特别是在低收入和中等收入国家，并阻碍整体市场成长。

另一个主要阻碍因素是与 AML 治疗相关的副作用。化疗仍然是 AML 治疗的主要手段，但它可能会导致严重的副作用，例如疲劳、噁心和感染疾病风险增加。这些副作用对患者的生活品质有重大影响，有时会导致治疗停止。即使是新的标靶治疗，儘管精度很高，但也会对患者的耐受性构成挑战。例如，维奈托克与其他治疗方法的组合虽然很有前景，但已显示出必须谨慎管理的副作用。

此外，严格的法规环境也是一项挑战。新药的核准过程非常严格，需要广泛的临床试验以确保安全性和有效性。虽然这些法规对于病人安全至关重要，但它们可能会减缓新药推向市场的速度。这些冗长的核准流程可能会对及时获得创新治疗造成障碍，并影响快速回应新治疗需求的能力。

全球急性骨髓性白血病治疗市场报告细分

该报告预测了2018年至2030年全球、区域和国家层面的收益成长，并对每个子区隔的最新行业趋势进行了分析。在这项研究中，Grand View Research 根据疾病、治疗、给药途径、最终用途和地区对全球急性骨髓性白血病治疗市场报告进行了细分。

  • 按疾病分类的展望（销售额，2018-2030）
  • 粒细胞白血病
  • 粒单核细胞白血病。
  • 早幼粒细胞白血病。
  • 单核细胞白血病。
  • 其他疾病。
  • 治疗展望（销售，2018-2030）
  • 化疗。

抗代谢药

烷化剂

细胞週期蛋白

其他的

  • 标靶治疗

FLT3抑制剂

还原

万弗利普塔

佐斯帕塔

IDH抑制剂

奇夫索沃

莱斯利迪亚

伊迪法

米洛塔格

BCL-2抑制剂

本克雷斯塔

Hedgehog途径抑制剂

达乌里主义

  • 免疫疗法

双特异性抗体

抗体-药物偶联物

免疫查核点抑制剂

嵌合体抗原受体 (CAR) T 细胞疗法

  • 其他治疗
  • 管理途径展望（销售，2018-2030）
  • 注射剂
  • 口服
  • 最终用途展望（收入，2018-2030）
  • 医院和诊所
  • 专业中心
  • 居家照护设置
  • 门诊护理中心
  • 地区展望（销售额，2018-2030）
  • 北美洲

美国。

加拿大

墨西哥

  • 欧洲

德国

英国

法国

义大利

西班牙

丹麦

瑞典

挪威

  • 亚太地区

中国

日本

印度

韩国

澳洲

泰国

  • 拉丁美洲

巴西

阿根廷

  • 中东和非洲 (MEA)

南非

沙乌地阿拉伯

阿拉伯聯合大公国

科威特

目录

第一章调查方法和范围

第 2 章执行摘要

第三章急性骨髓性白血病治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 急性骨髓性白血病治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章急性骨髓性白血病治疗市场：疾病估计与趋势分析

  • 急性骨髓性白血病治疗的全球市场：疾病仪表板
  • 全球急性骨髓性白血病治疗市场：疾病波动分析
  • 急性骨髓性白血病治疗的全球市场（按疾病和收益）
  • 粒细胞白血病
  • 粒单核细胞白血病
  • 早幼粒细胞白血病
  • 单核细胞白血病
  • 其他疾病

第五章急性骨髓性白血病治疗市场：治疗评估与趋势分析

  • 急性骨髓性白血病治疗的全球市场：治疗仪表板
  • 急性骨髓性白血病治疗的全球市场：治疗变异分析
  • 按治疗分類的收益
  • 化疗
  • 标靶治疗

5.5.2.1.1。

5.5.2.1.1.1. 2018-2030 年 Rydapt 市场估计与预测

5.5.2.1.2。

5.5.2.1.2.1. 2018-2030 年 Vanfrita 市场估计与预测

5.5.2.1.3.索斯帕塔

5.5.2.1.3.1. 2018-2030 年 Xospata 市场估计与预测

  • IDH抑制剂

5.5.3.1.1.蒂布索沃

5.5.3.1.1.1.2018-2030 年 Tibsovo 市场估计与预测

5.5.3.1.2.莱斯利迪亚

5.5.3.1.2.1. 2018-2030 年 Rezlidhia 市场估计与预测

5.5.3.1.3.伊迪法

5.5.3.1.3.1. 2018 年至 2030 年伊迪法市场估计与预测

  • 米洛塔格
  • BCL-2抑制剂

5.5.5.1.1。

5.5.5.1.1.1. 2018 年至 2030 年 Venclexta 市场估计与预测

  • Hedgehog途径抑制剂

5.5.6.1.1.道主义

5.5.6.1.1.1. 2018 年至 2030 年 Daurismo 市场估计与预测

  • 免疫疗法
    • 2018-2030年免疫治疗市场估计与预测

5.6.1.1.1. 2018-2030 年双特异性抗体市场估计与预测

5.6.1.4.1. 2018-2030 年免疫查核点抑制剂市场估计与预测

5.6.1.5.1. 2018 年至 2030 年嵌合嵌合体受体 (CAR) T 细胞治疗市场估计与预测

  • 其他治疗方法
    • 2018-2030 年其他治疗市场估计与预测

第六章急性骨髓性白血病治疗市场：给药途径估算及趋势分析

  • 急性骨髓性白血病治疗的全球市场：给药途径仪表板
  • 全球急性骨髓性白血病治疗市场：给药途径的变异分析
  • 途径的收益
  • 胃肠外的
  • 口服

第七章急性骨髓性白血病治疗市场：最终用途估计与趋势分析

  • 急性骨髓性白血病治疗的全球市场：最终用途仪表板
  • 全球急性骨髓性白血病治疗市场：最终用途变化分析
  • 按最终用途分類的收益
  • 医院和诊所
  • 专业中心
  • 居家照护环境

第 8 章急性骨髓性白血病治疗市场：按治疗、治疗层级和给药途径进行的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第9章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Astellas Pharma Inc.
    • Bristol Myers Squibb Company
    • Celgene Corporation
    • Daiichi Sankyo Company, Limited
    • Jazz Pharmaceuticals, plc
    • Novartis AG
    • Otsuka Pharmaceuticals Co., Ltd.
    • Pfizer, Inc.
    • Rigel Pharmaceuticals, Inc.
    • Merck &Co., Inc.
    • Sanofi
Product Code: GVR-4-68040-384-0

Market Size & Trends

The global acute myeloid leukemia treatment market size was estimated at USD 3.18 billion in 2023 and is expected to grow at a CAGR of 10.44% from 2024 to 2030. The increasing need for advanced therapeutics is also a high-impact rendering driver of this market. Rising incidences of acute myeloid leukemia therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, the increasing geriatric population base and growing unmet healthcare needs are expected to boost the market growth further. According to the estimates given by American Cancer Society in 2024, around 20,800 people were diagnosed with Acute Myeloid Leukemia.

The market for Acute Myeloid Leukemia (AML) treatment is driven by several key factors related to therapeutics and treatments. One significant driver is the continuous advancement and approval of novel therapies. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) in combination with standard chemotherapies for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML. This approval highlights the importance of targeted therapies that address specific genetic mutations in AML, improving patient outcomes and expanding treatment options. Such advancements not only enhance the efficacy of treatment regimens but also provide new hope for patients with limited options under conventional therapies.

Another major driver is the significant investment in research and development by pharmaceutical companies. For instance, a USD 6 million grant awarded in December 2023 for developing novel therapies targeting high-risk AML patients reflects the strong commitment to innovation in the field. This investment is crucial for discovering new treatment modalities and improving existing ones, thus driving market growth. Additionally, collaborations and partnerships among pharmaceutical companies, research institutions, and academic centers are pivotal in accelerating the development of new AML therapies, further stimulating market expansion.

Despite these advancements, the AML treatment market faces several restraints. One of the primary challenges is the high cost associated with new therapies. The development, approval, and commercialization of innovative treatments often come with substantial expenses, making them expensive for patients and healthcare systems. This financial burden can limit access to the latest treatments, especially in low- and middle-income countries, thereby hindering the overall market growth.

Another significant restraint is the adverse side effects associated with AML treatments. While chemotherapy remains a cornerstone of AML treatment, it can cause severe side effects such as fatigue, nausea, and increased risk of infections. These side effects can significantly impact the quality of life for patients and sometimes lead to treatment discontinuation. Even newer targeted therapies, despite their precision, can pose challenges to patient tolerance. For instance, the combination of venetoclax with other treatments, while promising, has shown side effects that necessitate careful management.

Furthermore, the stringent regulatory environment poses another challenge. The approval process for new drugs is rigorous, requiring extensive clinical trials to ensure safety and efficacy. While these regulations are essential for patient safety, they can delay the introduction of new therapies to the market. This prolonged approval process can be a barrier to the timely availability of innovative treatments, impacting the market's ability to respond quickly to emerging therapeutic needs.

Global Acute Myeloid Leukemia Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research segmented the global acute myeloid leukemia treatment market report based on disease, treatment, route of administration, end-use, and region.

  • Disease Outlook (Revenue, USD Million, 2018 - 2030)
  • Myeloblastic Leukemia
  • Myelomonocytic Leukemia
  • Promyelocytic Leukemia
  • Monocytic Leukemia
  • Other Diseases
  • Treatment Outlook (Revenue, USD Million, 2018 - 2030)
  • Chemotherapy

Anti-metabolites

Alkylating Agents

Anthracycline Drugs

Others

  • Targeted Therapy

FLT3 Inhibitors

Rydapt

Vanflyta

Xospata

IDH Inhibitors

Tibsovo

Rezlidhia

Idhifa

Mylotarg

BCL-2 Inhibitor

Venclexta

Hedgehog Pathway Inhibitor

Daurismo

  • Immunotherapy

Bispecific Antibodies

Antibody-drug Conjugates

Immune Checkpoint Inhibitors

Chimeric Antigen Receptor (CAR) T-cell Therapy

  • Other Treatments
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Parenteral
  • Oral
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital and Clinics
  • Specialty Centers
  • Homecare Settings
  • Ambulatory Care Centers
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

Germany

U.K.

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. Route of Administration outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of acute myeloid leukemia
      • 3.2.1.2. Advancements in diagnostic techniques
      • 3.2.1.3. Growing investments in R&D techniques
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Limited treatment options
  • 3.3. Acute Myeloid Leukemia Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Estimates & Trend Analysis

  • 4.1. Global Acute Myeloid Leukemia Treatment Market: Disease Dashboard
  • 4.2. Global Acute Myeloid Leukemia Treatment Market: Disease Movement Analysis
  • 4.3. Global Acute Myeloid Leukemia Treatment Market by Disease, Revenue
  • 4.4. Myeloblastic Leukemia
    • 4.4.1. Myeloblastic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Myelomonocytic Leukemia
    • 4.5.1. Myelomonocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Promyelocytic Leukemia
    • 4.6.1. Promyelocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Monocytic Leukemia
    • 4.7.1. Monocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other Diseases
    • 4.8.1. Other diseases market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Estimates & Trend Analysis

  • 5.1. Global Acute Myeloid Leukemia Treatment Market: Treatment Dashboard
  • 5.2. Global Acute Myeloid Leukemia Treatment Market: Treatment Movement Analysis
  • 5.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Anti-metabolites
      • 5.4.2.1. Anti-metabolites market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Alkylating agents
      • 5.4.3.1. Alkylating agents market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Anthracycline drugs
      • 5.4.4.1. Anthracycline drugs market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. FLT3 inhibitors
      • 5.5.2.1. FLT3 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.1.1. Rydapt

5.5.2.1.1.1. Rydapt market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.1.2. Vanflyta

5.5.2.1.2.1. Vanflyta market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.1.3. Xospata

5.5.2.1.3.1. Xospata market estimates and forecasts 2018 to 2030 (USD Million)

    • 5.5.3. IDH inhibitors
      • 5.5.3.1. IDH inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

5.5.3.1.1. Tibsovo

5.5.3.1.1.1. Tibsovo market estimates and forecasts 2018 to 2030 (USD Million)

5.5.3.1.2. Rezlidhia

5.5.3.1.2.1. Rezlidhia market estimates and forecasts 2018 to 2030 (USD Million)

5.5.3.1.3. Idhifa

5.5.3.1.3.1. Idhifa market estimates and forecasts 2018 to 2030 (USD Million)

    • 5.5.4. Mylotarg
      • 5.5.4.1. Mylotarg market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. BCL-2 inhibitor
      • 5.5.5.1. BCL-2 inhibitor market estimates and forecasts 2018 to 2030 (USD Million)

5.5.5.1.1. Venclexta

5.5.5.1.1.1. Venclexta market estimates and forecasts 2018 to 2030 (USD Million)

    • 5.5.6. Hedgehog pathway inhibitor
      • 5.5.6.1. Hedgehog pathway inhibitor market estimates and forecasts 2018 to 2030 (USD Million)

5.5.6.1.1. Daurismo

5.5.6.1.1.1. Daurismo market estimates and forecasts 2018 to 2030 (USD Million)

  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.6.1.1. Bispecific antibodies

5.6.1.1.1. Bispecific antibodies market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.6.1.2. Antibody-drug conjugates
      • 5.6.1.3. Antibody-drug conjugates market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.6.1.4. Immune checkpoint inhibitors

5.6.1.4.1. Immune checkpoint inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.6.1.5. Chimeric antigen receptor (CAR) T-cell therapy

5.6.1.5.1. Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecasts 2018 to 2030 (USD Million)

  • 5.7. Other Treatments
    • 5.7.1. Other treatments market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Dashboard
  • 6.2. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Estimates & Trend Analysis

  • 7.1. Global Acute Myeloid Leukemia Treatment Market: End Use Dashboard
  • 7.2. Global Acute Myeloid Leukemia Treatment Market: End Use Movement Analysis
  • 7.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts by End Use, Revenue (USD Million)
  • 7.4. Hospital and Clinics
    • 7.4.1. Hospital and clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Specialty Centers
    • 7.5.1. Specialty Centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Homecare Setting
    • 7.6.1. Homecare setting market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Vendor Landscape
    • 9.2.1. List of key distributors and channel partners
    • 9.2.2. Key customers
    • 9.2.3. Key company market share analysis, 2023
    • 9.2.4. Astellas Pharma Inc.
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Bristol Myers Squibb Company
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Celgene Corporation
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Daiichi Sankyo Company, Limited
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Jazz Pharmaceuticals, plc
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Novartis AG
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Otsuka Pharmaceuticals Co., Ltd.
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives
    • 9.2.11. Pfizer, Inc.
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Product benchmarking
      • 9.2.11.4. Strategic initiatives
    • 9.2.12. Rigel Pharmaceuticals, Inc.
      • 9.2.12.1. Company overview
      • 9.2.12.2. Financial performance
      • 9.2.12.3. Product benchmarking
      • 9.2.12.4. Strategic initiatives
    • 9.2.13. Merck & Co., Inc.
      • 9.2.13.1. Company overview
      • 9.2.13.2. Financial performance
      • 9.2.13.3. Product benchmarking
      • 9.2.13.4. Strategic initiatives
    • 9.2.14. Sanofi
      • 9.2.14.1. Company overview
      • 9.2.14.2. Financial performance
      • 9.2.14.3. Product
      • 9.2.14.4. Benchmarking
      • 9.2.14.5. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 4 North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 8 U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 12 Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 16 Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 21 Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 25 Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 29 UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 33 France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 37 Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 41 Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 45 Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Denmark Acute Myeloid Leukemia Treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 49 Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 50 Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 53 Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 62 China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 66 Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 70 India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 71 India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 74 South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 75 South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 78 Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 79 Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 82 Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 84 Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 86 Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 87 Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 88 Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 91 Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 92 Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 95 Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 96 Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 98 MEA acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 100 MEA acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 101 MEA acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 MEA acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 104 South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 105 South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 112 UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 113 UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 116 Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 117 Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Acute myeloid leukemia treatment market: market outlook
  • Fig. 14 Acute myeloid leukemia treatment competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Acute myeloid leukemia treatment market driver impact
  • Fig. 18 Acute myeloid leukemia treatment market restraint impact
  • Fig. 19 Acute myeloid leukemia treatment market: disease movement analysis
  • Fig. 20 Acute myeloid leukemia treatment market: disease outlook and key takeaways
  • Fig. 21 Myeloblastic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Myelomonocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Promyelocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Monocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Acute myeloid leukemia treatment market: Treatment movement analysis
  • Fig. 28 Acute myeloid leukemia treatment market: Treatment outlook and key takeaways
  • Fig. 29 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Anti-metabolites market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Anthracycline drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 FLT3 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Rydapt market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Vanflyta market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Xospata market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 IDH inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Tibsovo market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Rezlidhia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Idhifa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Mylotarg market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 BCL-2 inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Venclexta market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Hedgehog pathway inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Daurismo market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Bispecific antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Antibody-drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Immune checkpoint inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Other treatments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Acute myeloid leukemia treatment market: Route of administration movement analysis
  • Fig. 55 Acute myeloid leukemia treatment market: Route of administration outlook and key takeaways
  • Fig. 56 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Acute myeloid leukemia treatment market: End Use movement analysis
  • Fig. 59 Acute myeloid leukemia treatment market: End Use outlook and key takeaways
  • Fig. 60 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Specialty centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Homecare setting market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Ambulatory care centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Global acute myeloid leukemia treatment market: Regional movement analysis
  • Fig. 65 Global acute myeloid leukemia treatment market: Regional outlook and key takeaways
  • Fig. 66 Global acute myeloid leukemia treatment market share and leading players
  • Fig. 67 North America, by country
  • Fig. 68 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 U.S. key country dynamics
  • Fig. 70 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Canada key country dynamics
  • Fig. 72 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Mexico key country dynamics
  • Fig. 74 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 UK key country dynamics
  • Fig. 77 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Germany key country dynamics
  • Fig. 79 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 France key country dynamics
  • Fig. 81 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Italy key country dynamics
  • Fig. 83 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Spain key country dynamics
  • Fig. 85 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Denmark key country dynamics
  • Fig. 87 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Sweden key country dynamics
  • Fig. 89 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Norway key country dynamics
  • Fig. 91 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 China key country dynamics
  • Fig. 94 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Japan key country dynamics
  • Fig. 96 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 India key country dynamics
  • Fig. 98 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Thailand key country dynamics
  • Fig. 100 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 South Korea key country dynamics
  • Fig. 102 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Australia key country dynamics
  • Fig. 104 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Brazil key country dynamics
  • Fig. 107 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Argentina key country dynamics
  • Fig. 109 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 South Africa key country dynamics
  • Fig. 112 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Saudi Arabia key country dynamics
  • Fig. 114 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 UAE key country dynamics
  • Fig. 116 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Kuwait key country dynamics
  • Fig. 118 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Market share of key market players- acute myeloid leukemia treatment market